24608 Federal Register / Vol. 72, No. 85 / Thursday, May 3, 2007 / Notices 

approved [by the FDA] for medical use 

and placed in a Schedule other than 

Schedule I, DEA cannot grant an 

application to manufacture * * * these 

substances to anyone who seeks to 

manufacture [them] for the purpose of 

distributing * * * or dispensing [them] 

to[ ] ‘patients.’ ’’ Id. 

The Government also argued that 

marijuana and tetrahydrocannabinols 

are Schedule I controlled substances 

under Washington law and that the 

State’s Medical Use of Marijuana Act 

creates only ‘‘a narrow exception to the 

classification of marijuana as a Schedule 

I controlled substance.’’ Id. at 5–6. 

According to the Government, the 

exception allows only a ‘‘qualifying 

patient’’ to possess marijuana, and such 

person may only ‘‘ ‘possess no more 

marijuana than is necessary for the 

patient’s personal, medical use, not 

exceeding the amount necessary for a 

sixty-day supply.’ ’’ Id. at 6 (quoting 

RCW section 69.51A.040(2)(b)). The 

Government thus contends that 

Respondent’s proposed activities go 

‘‘well beyond what is permitted to be 

manufactured under applicable 

Washington * * * law,’’ and thus 

Respondent would be non-compliant 

with state law. Id. (citing 21 U.S.C. 

823(a)(2)) (requiring Attorney General to 

consider ‘‘compliance with applicable 

State law’’ in considering application to 

manufacture Schedule I controlled 

substances). 

In its submission, Respondent’s 

owners stated that ‘‘there are no 

witnesses,’’ that ‘‘[a]ll documents have 

been submitted,’’ and that ‘‘[o]ther 

testimony ha[d] been submitted in the’’ 

questionnaire they had previously sent 

to DEA. Resp. Letter 1 (July 11, 2006). 

Respondent’s owners further stated that 

it was their ‘‘intention to manufacture, 

package and sell [marijuana] to the 

various authorized outlets (state 

pharmacies within the state of 

Washington).’’ Id. With respect to the 

legal issue presented, Respondent stated 

that it is ‘‘[t]he position and law of the 

State of Washington * * * that certain 

qualified persons in this State have the 

right as given by the voice of the people 

to possess and use marijuana for 

specific medical needs as described in 

Washington State law.’’ Id. Respondent 

further maintained that ‘‘DEA should 

allow the State of Washington and 

[itself] to engage [in] the legal and 

correct distribution of marijuana.’’ Id. 

Concluding that there were no 

material facts in dispute, the ALJ 

granted the Government’s motion. As 

the ALJ explained, marijuana and 

tetrahydrocannabinols ‘‘have a high 

potential for abuse, have no currently 

accepted medical use in treatment, and 

lack safety for use in treatment under 

medical supervision.’’ ALJ Dec. at 3. 

Because ‘‘these substances cannot be 

manufactured for distribution to 

patients for medical use,’’ the ALJ 

concluded that DEA ‘‘cannot register an 

applicant with the intention to 

manufacture and distribute contrary to 

federal law.’’ Id. Finally, the ALJ also 

held that the Washington state law 

exception does not ‘‘extend to the 

manufacturing of these substances and 

therefore Respondent lacks state 

authority’’ to conduct its proposed 

activity. The ALJ thus recommended 

that I deny Respondent’s application 

and forwarded the record to me for final 

agency action. Neither party filed 

exceptions. 

Having considered the record as a 

whole, I adopt the ALJ’s opinion in its 

entirety and deny Respondent’s 

application. Section 303(a) of the 

Controlled Substances Act provides that 

the ‘‘Attorney General shall register an 

applicant to manufacture controlled 

substances in schedule I or II if he 

determines that such registration is 

consistent with the public interest.’’ 21 

U.S.C. 823(a). While Congress provided 

six factors to be considered in 

determining the public interest, id., it is 

well settled that I may rely on any one 

or a combination of factors, and may 

give each factor the weight I deem 

appropriate in determining whether an 

application for registration should be 

denied. See ALRA Laboratories, Inc., 59 

FR 50620, 50621 (1994). Moreover, I am 

‘‘not required to make findings as to all 

of the factors.’’ Hoxie v. DEA, 419 F.3d 

477, 482 (6th Cir. 2005); Morall v. DEA, 

412 F.3d 165, 173–74 (D.C. Cir. 2005). 

Here, it is clear that Respondent’s 

proposed activity would not comply 

with applicable Federal and State laws 

and would be inconsistent with public 

health and safety. See 21 U.S.C. 

823(a)(2) & (6). Congress placed 

marijuana (and tetrahydrocannabinols) 

on Schedule I based on its 

determination that both substances have 

‘‘ ‘no currently accepted medical use’ at 

all.’’ Oakland Cannabis Buyers, 532 U.S. 

at 483, 491 (2001). Until Congress 

revises that determination, it is a federal 

criminal offense to manufacture either 

of these substances for any purpose 

other than to supply an FDA preapproved research project. See Gonzales 

v. Raich, 545 U.S. 1, 14 (2005). 

Moreover, it also appears that 

Respondent’s proposed activities would 

violate Washington law. See State v. 

Tracy, 147 P.3d 559, 561–62 (Wash. 

2006) (upholding conviction for 

possession and manufacturing of 

marijuana because ‘‘only qualifying 

patients are entitled to the defense 

under the act’’). Accordingly, 

Respondent’s registration would be 

inconsistent with the public interest. 

See 21 U.S.C. 823(a). 

Order 

Pursuant to the authority vested in me 

by 21 U.S.C. 823(a), as well as by 28 

CFR 0.100(b) & 0.104, I hereby order 

that the application of Green Acres 

Farm, Inc., for a DEA Certificate of 

Registration to manufacture marijuana 

and tetrahydrocannabinols be, and it 

hereby is, denied. This order is effective 

June 4, 2007. 

Dated: April 25, 2007. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E7–8454 Filed 5–2–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–290R] 

Controlled Substances: Proposed 

Revised Aggregate Production Quotas 

for 2007 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of proposed revised 2007 

aggregate production quotas. 

SUMMARY: This notice proposes revised 

2007 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). 

DATES: Written comments must be 

postmarked, and electronic comments 

must be sent, on or before May 24, 2007. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–290R on all written and 

electronic correspondence. Written 

comments being sent via regular mail 

should be sent to the Deputy Assistant 

Administrator, Office of Diversion 

Control, Drug Enforcement 

Administration, Washington, DC 20537, 

Attention: DEA Federal Register 

Representative/ODL. Written comments 

sent via express mail should be sent to 

DEA Headquarters, Attention: DEA 

Federal Register Representative/ODL, 

2401 Jefferson-Davis Highway, 

Alexandria, VA 22301. Comments may 

be directly sent to DEA electronically by 

sending an electronic message to 

dea.diversion.policy@usdoj.gov. 

Comments may also be sent 

electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

mmaher on DSK3CLS3C1PROD with $$_JOB

Federal Register / Vol. 72, No. 85 / Thursday, May 3, 2007 / Notices 24609 

document is also available at the http:// 

www.regulations.gov Web site. DEA will 

accept attachments to electronic 

comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, PhD, Chief, Drug 

and Chemical Evaluation Section, Drug 

Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant to 28 CFR 

0.104. 

On December 11, 2006, a notice of 

established initial 2007 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (71 

FR 71559). This notice stipulated that 

the DEA would adjust the quotas in 

early 2007 as provided for in 21 CFR 

Part 1303. 

The proposed revised 2007 aggregate 

production quotas represent those 

quantities of controlled substances in 

schedules I and II that may be produced 

in the United States in 2007 to provide 

adequate supplies of each substance for: 

The estimated medical, scientific, 

research and industrial needs of the 

United States; lawful export 

requirements; and the establishment 

and maintenance of reserve stocks. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

The proposed revisions are based on 

a review of 2006 year-end inventories, 

2006 disposition data submitted by 

quota applicants, estimates of the 

medical needs of the United States, 

product development, and other 

information available to the DEA. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by 28 CFR 0.100, and redelegated 

to the Deputy Administrator pursuant to 

28 CFR 0.104, the Deputy Administrator 

hereby proposes the following revised 

2007 aggregate production quotas for the 

following controlled substances, 

expressed in grams of anhydrous acid or 

base: 

Basic class—Schedule I Previously established 

initial 2007 quotas 

Proposed revised 

2007 quotas 

2,5–Dimethoxyamphetamine ........................................................................................................... 2,001,000 g 2,001,000 g 

2,5–Dimethoxy-4-ethylamphetamine (DOET) .................................................................................. 2 2 

2,5–Dimethoxy-4-(n)-propylthiophenethylamine (2C-T–7) .............................................................. 10 10 

3–Methylfentanyl .............................................................................................................................. 2 2 

3–Methylthiofentanyl ........................................................................................................................ 2 2 

3,4–Methylenedioxyamphetamine (MDA) ........................................................................................ 20 20 

3,4–Methylenedioxy-N-ethylamphetamine (MDEA) ......................................................................... 10 10 

3,4–Methylenedioxymethamphetamine (MDMA) ............................................................................. 22 22 

3,4,5–Trimethoxyamphetamine ....................................................................................................... 2 2 

4–Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................. 2 2 

4–Bromo-2,5-dimethoxyphenethylamine (2–CB) ............................................................................. 7 2 

4–Methoxyamphetamine .................................................................................................................. 77 77 

4–Methylaminorex ............................................................................................................................ 2 2 

4–Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................. 12 12 

5–Methoxy-3,4-methylenedioxyamphetamine ................................................................................. 2 2 

5–Methoxy-N,N-diisopropyltryptamine ............................................................................................. 5 5 

Acetyl-alpha-methylfentanyl ............................................................................................................. 2 2 

Acetyldihydrocodeine ....................................................................................................................... 2 2 

Acetylmethadol ................................................................................................................................ 2 2 

Allylprodine ...................................................................................................................................... 2 2 

Alphacetylmethadol .......................................................................................................................... 2 2 

Alpha-ethyltryptamine ...................................................................................................................... 2 2 

Alphameprodine ............................................................................................................................... 2 2 

Alphamethadol ................................................................................................................................. 3 3 

Alpha-methylfentanyl ....................................................................................................................... 2 2 

Alpha-methylthiofentanyl .................................................................................................................. 2 2 

Alpha-methyltryptamine ................................................................................................................... 5 5 

Aminorex .......................................................................................................................................... 8 8 

Benzylmorphine ............................................................................................................................... 2 2 

Betacetylmethadol ........................................................................................................................... 2 2 

Beta-hydroxy-3-methylfentanyl ........................................................................................................ 2 2 

Beta-hydroxyfentanyl ....................................................................................................................... 2 2 

Betameprodine ................................................................................................................................. 2 2 

Betamethadol ................................................................................................................................... 2 2 

Betaprodine ...................................................................................................................................... 2 2 

Bufotenine ........................................................................................................................................ 8 8 

Cathinone ......................................................................................................................................... 3 3 

Codeine-N-oxide .............................................................................................................................. 302 302 

Diethyltryptamine ............................................................................................................................. 2 2 

Difenoxin .......................................................................................................................................... 50 50 

Dihydromorphine .............................................................................................................................. 2,549,000 2,549,000 

Dimethyltryptamine .......................................................................................................................... 3 3 

Gamma-hydroxybutyric acid ............................................................................................................ 13,100,000 13,100,000 

Heroin .............................................................................................................................................. 5 5 

Hydromorphinol ................................................................................................................................ 3,000 3,000 

Hydroxypethidine ............................................................................................................................. 2 2 

Ibogaine ........................................................................................................................................... 1 1 

mmaher on DSK3CLS3C1PROD with $$_JOB

24610 Federal Register / Vol. 72, No. 85 / Thursday, May 3, 2007 / Notices 

Basic class—Schedule I Previously established 

initial 2007 quotas 

Proposed revised 

2007 quotas 

Lysergic acid diethylamide (LSD) .................................................................................................... 61 61 

Marihuana ........................................................................................................................................ 4,500,000 4,500,000 

Mescaline ......................................................................................................................................... 2 2 

Methaqualone .................................................................................................................................. 10 10 

Methcathinone ................................................................................................................................. 4 4 

Methyldihydromorphine .................................................................................................................... 2 2 

Morphine-N-oxide ............................................................................................................................ 310 310 

N,N-Dimethylamphetamine .............................................................................................................. 7 7 

N-Ethylamphetamine ....................................................................................................................... 2 2 

N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................. 2 2 

Noracymethadol ............................................................................................................................... 2 2 

Norlevorphanol ................................................................................................................................. 52 52 

Normethadone ................................................................................................................................. 2 2 

Normorphine .................................................................................................................................... 16 16 

Para-fluorofentanyl ........................................................................................................................... 2 2 

Phenomorphan ................................................................................................................................ 2 2 

Pholcodine ....................................................................................................................................... 2 2 

Psilocybin ......................................................................................................................................... 7 7 

Psilocyn ............................................................................................................................................ 7 7 

Tetrahydrocannabinols .................................................................................................................... 312,500 312,500 

Thiofentanyl ..................................................................................................................................... 2 2 

Trimeperidine ................................................................................................................................... 2 2 

Basic class—Schedule II Previously established 

initial 2007 quotas 

Proposed revised 

2007 quotas 

1–Phenylcyclohexylamine ................................................................................................................ 2 g 2 g 

Alfentanil .......................................................................................................................................... 7,200 7,200 

Alphaprodine .................................................................................................................................... 2 2 

Amobarbital ...................................................................................................................................... 3 3 

Amphetamine (for sale) ................................................................................................................... 17,000,000 17,000,000 

Amphetamine (for conversion) ........................................................................................................ 0 2,760,000 

Cocaine ............................................................................................................................................ 286,000 286,000 

Codeine (for sale) ............................................................................................................................ 39,605,000 39,605,000 

Codeine (for conversion) ................................................................................................................. 59,000,000 59,000,000 

Dextropropoxyphene ........................................................................................................................ 120,000,000 120,000,000 

Dihydrocodeine ................................................................................................................................ 2,435,000 2,435,000 

Diphenoxylate .................................................................................................................................. 828,000 828,000 

Ecgonine .......................................................................................................................................... 83,000 83,000 

Ethylmorphine .................................................................................................................................. 2 2 

Fentanyl ........................................................................................................................................... 1,428,000 1,428,000 

Glutethimide ..................................................................................................................................... 2 2 

Hydrocodone (for sale) .................................................................................................................... 42,000,000 42,000,000 

Hydrocodone (for conversion) ......................................................................................................... 1,500,000 1,500,000 

Hydromorphone ............................................................................................................................... 3,300,000 3,300,000 

Isomethadone .................................................................................................................................. 2 2 

Levo-alphacetylmethadol (LAAM) .................................................................................................... 6 6 

Levomethorphan .............................................................................................................................. 5 5 

Levorphanol ..................................................................................................................................... 6,000 6,000 

Lisdexamfetamine ............................................................................................................................ 0 6,200,000 

Meperidine ....................................................................................................................................... 9,753,000 9,753,000 

Metazocine ....................................................................................................................................... 1 1 

Methadone (for sale) ....................................................................................................................... 25,000,000 25,000,000 

Methadone Intermediate .................................................................................................................. 26,000,000 26,000,000 

Methamphetamine ........................................................................................................................... 3,130,000 3,130,000 

[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 45,000 grams for methamphetamine (for sale)] 

Methylphenidate ............................................................................................................................... 35,000,000 g 35,000,000 g 

Morphine (for sale) .......................................................................................................................... 35,000,000 35,000,000 

Morphine (for conversion) ................................................................................................................ 110,774,000 110,774,000 

Nabilone ........................................................................................................................................... 3,002 3,002 

Noroxymorphone (for sale) .............................................................................................................. 1,002 1,002 

Noroxymorphone (for conversion) ................................................................................................... 11,000,000 11,000,000 

Opium .............................................................................................................................................. 1,400,000 1,400,000 

Oxycodone (for sale) ....................................................................................................................... 56,000,000 56,000,000 

Oxycodone (for conversion) ............................................................................................................ 25,000,000 25,000,000 

Oxymorphone .................................................................................................................................. 1,800,000 1,800,000 

Oxymorphone (for conversion) ........................................................................................................ 15,300,000 15,300,000 

Pentobarbital .................................................................................................................................... 28,000,000 28,000,000 

Phencyclidine ................................................................................................................................... 2,021 2,021 

Phenmetrazine ................................................................................................................................. 2 2 

mmaher on DSK3CLS3C1PROD with $$_JOB

Federal Register / Vol. 72, No. 85 / Thursday, May 3, 2007 / Notices 24611 

Basic class—Schedule II Previously established 

initial 2007 quotas 

Proposed revised 

2007 quotas 

Racemethorphan ............................................................................................................................. 2 2 

Remifentanil ..................................................................................................................................... 5,000 5,000 

Secobarbital ..................................................................................................................................... 2 2 

Sufentanil ......................................................................................................................................... 12,300 12,300 

Thebaine .......................................................................................................................................... 102,000,000 102,000,000 

The Deputy Administrator further 

proposes that aggregate production 

quotas for all other schedules I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 remain at 

zero. 

All interested persons are invited to 

submit their comments in writing or 

electronically regarding this proposal 

following the procedures in the 

ADDRESSES section of this document. A 

person may object to or comment on the 

proposal relating to any of the abovementioned substances without filing 

comments or objections regarding the 

others. If a person believes that one or 

more of these issues warrant a hearing, 

the individual should so state and 

summarize the reasons for this belief. 

In the event that comments or 

objections to this proposal raise one or 

more issues which the Deputy 

Administrator finds warrant a hearing, 

the Deputy Administrator shall order a 

public hearing by notice in the Federal 

Register, summarizing the issues to be 

heard and setting the time for the 

hearing as per 21 CFR 1303.13(c). 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will not have a 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by State, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $120,000,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: April 25, 2007. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. E7–8422 Filed 5–2–07; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Federal Bureau of Investigation 

Meeting of the Compact Council for the 

National Crime Prevention and Privacy 

Compact 

AGENCY: Federal Bureau of 

Investigation. 

ACTION: Meeting notice. 

SUMMARY: The purpose of this notice is 

to announce a meeting of the National 

Crime Prevention and Privacy Compact 

Council (Council) created by the 

National Crime Prevention and Privacy 

Compact Act of 1998 (Compact). Thus 

far, the Federal Government and 27 

states are parties to the Compact which 

governs the exchange of criminal history 

records for licensing, employment, and 

similar purposes. The Compact also 

provides a legal framework for the 

establishment of a cooperative federalstate system to exchange such records. 

The United States Attorney General 

appointed 15 persons from federal and 

state agencies to serve on the Council. 

The Council will prescribe system rules 

and procedures for the effective and 

proper operation of the Interstate 

Identification Index System. 

Matters for discussion are expected to 

include: 

(1) Establishment of State 

Noncriminal Justice Audit Programs 

(2) New National Child Protection 

Act/Volunteers for Children Act 

Guidelines 

(3) New Compact Council Strategic 

Plan 

The meeting will be open to the 

public on a first-come, first-seated basis. 

Any member of the public wishing to 

file a written statement with the Council 

or wishing to address this session of the 

Council should notify Mr. Todd C. 

Commodore at (304) 625–2803, at least 

24 hours prior to the start of the session. 

The notification should contain the 

requestor’s name and corporate 

designation, consumer affiliation, or 

government designation, along with a 

short statement describing the topic to 

be addressed and the time needed for 

the presentation. Requesters will 

ordinarily be allowed up to 15 minutes 

to present a topic. 

DATES AND TIMES: The Council will meet 

in open session from 9 a.m. until 5 p.m., 

on May 23–24, 2007. 

ADDRESSES: The meeting will take place 

at the Hyatt Regency Louisville, 320 

West Jefferson Street, Louisville, 

Kentucky, telephone (502) 581–1234. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries may be addressed to Mr. Todd 

C. Commodore, FBI Compact Officer, 

Compact Council Office, Module B3, 

1000 Custer Hollow Road, Clarksburg, 

West Virginia 26306–0148, telephone 

(304) 625–2803, facsimile (304) 625– 

2539. 

mmaher on DSK3CLS3C1PROD with $$_JOB